variants of uncertain significance (VUS) limit the reach of genetic testing in clinical practice. 20
The VUS for Hypertrophic Cardiomyopathy (HCM), the most common familial heart disease, 21
constitute over 60% of entries for missense variants shown in ClinVar database. We have 22 studied a novel VUS (c.1809T>G-p.I603M) in the most frequently mutated gene in HCM, 23
MYBPC3, which codes for cardiac myosin-binding protein C (cMyBPC). Our determinations 24 of pathogenicity integrate bioinformatics evaluation and functional studies of RNA splicing 25 and protein thermodynamic stability. In silico prediction and mRNA analysis indicated no 26 alteration of RNA splicing induced by the variant. At the protein level, the p.I603M mutation 27 maps to the C4 domain of cMyBPC. Although the mutation does not perturb much the overall 28 structure of the C4 domain, the stability of C4 I603M is severely compromised as detected by 29 circular dichroism and differential scanning calorimetry experiments. Taking into account the 30 highly destabilizing effect of the mutation in the structure of C4, we propose reclassification 31 of variant p.I603M as likely pathogenic. Looking into the future, the workflow described here 32
can be used to refine the assignment of pathogenicity of variants of uncertain significance in 33
MYBPC3. 34 35
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1. Introduction 39 Hypertrophic cardiomyopathy (HCM) constitutes the most common inherited disease of the 40 myocardium with an estimated prevalence ranging from 1:500 to 1:200 1,2 . Although the 41 clinical manifestations of HCM are highly variable, the disease is characterized by left 42 ventricular hypertrophy (LVH) in the absence of triggers, such as hypertension, and in some 43 cases sudden cardiac death (SCD) may be the first manifestation of the disease 3-5 . Importantly, 44
HCM has a very strong genetic component, and up to 60% of patients who meet the diagnostic 45 criteria have pathogenic mutation in genes coding for sarcomere proteins 6-8 . The genetic 46 testing for HCM is key to identify patients at high risk before the occurrence of clinical 47 manifestations. Thus, the clinical role of genetic testing largely centers on family screening to 48 facilitate presymptomatic diagnosis of family members, clinical surveillance and reproductive 49 advice 9-12 . Due to the increased complexity of analysis and interpretation of genetic tests, 50 general guidelines for the interpretation of variants have been published by the American 51 College of Medical Genetics and Genomics (ACMG) and the Association for Molecular 52 Pathology (AMP) 13, 14 . By applying the proposed score, variants can be classified into five 53 main groups including pathogenic, likely pathogenic, likely benign, benign, and uncertain 54 significance variants (VUS 
Bioinformatics predictions of pathogenicity at the protein level 103
Missense mutation at the protein level was evaluated with three independent bioinformatics 104 tools that predict possible impact of amino acid substitutions on the structure and function of 105 the protein (PolyPhen-2, SIFT, Provean). PolyPhen-2 (Polymorphism Phenotyping v2) 106 evaluates the impact of amino acid allelic variants via analysis of multiple sequence alignments 107 and protein 3D-structures 32 . SIFT (Sorting Intolerant From Tolerant) presumes that important 108 amino acids will be conserved in the protein family, so changes at well-conserved positions 109 tend to be predicted as deleterious 33 
Protein expression and purification for biophysical characterization 120
The recombinant WT and mutant I603M C4 domains (Table 1) were engineered and purified 121 for thermodynamic analysis. With that aim, the cDNA fragment including exons 18 and 19 of 122 MYBPC3, was amplified from cardiac RNA with cMyBPC_C4_Fw and cMyBPC _C4 _Rv 123 oligonucleotides (Table 2) and cloned in a custom-modified pQE80L (Qiagen) using BamHI 124
and BglII restriction sites. I603M mutant cDNA was generated by PCR site-directed 125 mutagenesis. Final constructs were verified by Sanger sequencing. Proteins were expressed in 126 BLR (DE3) E. coli strain and purified from the soluble fraction using nickel-nitrilotriacetic 127 acid (Ni-NTA) chromatography (Qiagen) with a column volume of 3 mL and pre-equilibrated 128 with phosphate buffer (50 mM sodium phosphate pH 7 and 300 mM NaCl) supplemented with 129 10 mM DTT. Elution was performed in two steps with increasing imidazole concentration 130
(from 20mM to 250mM). Further purification was achieved by size-exclusion chromatography 131
in an AKTA Pure 25L system using a Superdex 200 Increase 10/300 GL column (GE 132
Healthcare). The proteins were eluted in phosphate buffer buffer (20 mM sodium phosphate 133 pH 6.5, 50 mM NaCl), which was used both in circular dichroism (CD) and differential 134 scanning calorimetry (DSC) experiments. All domains were at least 90-95% pure as estimated 135
by SDS-PAGE analysis. 136 137
Circular Dichroism (CD) 138
CD spectra of domain C4 were collected with a Jasco-810 spectropolarimeter. The temperature 139 was controlled using a Peltier thermoelectric system. Purified proteins in phosphate were 140 loaded into a 0.1cm or 1cm path-length quartz cuvettes for data collection in the far-UV (195-141 250 nm) or the near-UV (250-350nm), respectively. Protein concentration was 0.3 mg/mL (far-142 UV) and 1 mg/mL (near-UV). Spectra were collected for the protein samples and buffer control 143 at 25°C and 85°C with four accumulations of data. The buffer baseline spectrum was subtracted 144 from each protein spectrum at each corresponding temperature to correct for the background 145 signal. Thermal denaturation analyses were carried out collecting the variations of ellipticity at 146 230 nm as a function of temperature (25°C-85°C, at a rate of 30ºC/h). Protein refolding was 147 analysed with a temperature ramp-down (85°C-25°C) at the same speed. We plotted the 148 ellipticity versus temperature and the data points were fit with a Boltzmann sigmoidal curve 149
using Igor Pro software to obtain midpoint unfolding temperatures (Tm). The changes in CD as 150 a function of temperature can be used to determine the van't Hoff enthalpy (ΔHv) of unfolding 151
considering ΔCp = 0 37 . 152 153 2.7 Differential scanning calorimetry (DSC) 154
Calorimetric measurements were performed using a Microcal VP-DSC differential scanning 155 calorimeter with 0.5 mL cells. Experiments were done by increasing temperature from 25°C to 156 85°C at a rate of 30ºC/h , using 0.085 mM (1 mg/mL) protein concentration in phosphate buffer. 157
The reversibility of the thermal transitions was assessed by reheating of the sample 158 immediately after cooling from the previous scan, using the same rate of temperature change. 159
The calorimetric traces were corrected for the instrumental background by subtracting a scan 160 with buffer in both cells. The temperature dependence of the excess heat capacity was analysed 161
using Origin software (MicroCal, Northampton, MA (Table 3 ). Although segregation analysis was possible, the family tree was not 177 informative ( Figure 1, A) . The genetic screening of other family members evidenced the 178 presence of the c.1809T>G-p.I603M variant in two affected subjects in heterozygosis with 179 another MYBPC3 mutation, p.T33RfsX15. One subject (III.5 in Figure 1 (Figure 1, B) . Similar results were obtained for the prediction of 204 activation of cryptic splicing sites (data not shown). To verify predictions, we amplified the 205 fragment spanning from exon 15 to exon 21 using mRNA isolated from peripheral blood. The 206 gel electrophoresis showed an identical migration pattern of both mutant carrier and a healthy 207 control (Figure 1, C right) . Sanger sequencing confirmed the correct splicing in both cases 208 (Figure 1, C left) . 209 210 3.3 C4 WT and C4 I603M share a similar β-sheet rich structure 211
The p.I603M is a missense variant that affects a highly conserved residue in the central domain 212
C4 of cMyBPC (Figure 2, A, D) . Since the structure of domain C4 is not known, to predict 213
how the protein structure might be affected by the p.I603M mutation, the homology modelling 214 of the domain was carried out using I-TASSER. The resulting model showed that the C4 215 domain adopts an Ig-like folding (Figure 2, B ) 49 . The predicted structure of C4 I603M is very 216 similar to WT. The RMSD of both predictions with respect to the template is 1.9±1.6Å for WT 217 and 2.0±1.6Å for p.I603M. The RMSD of WT and p.I603M homology models is 0.2634Å. 218
Both isoleucine and methione share similar physico-chemical properties, suggesting no effect 219 on protein structure by mutation p.I603M. Still, it is interesting to observe that Ile603 is buried 220 in the core of the WT domain (Figure 2, B) , so a mutation affecting this residue may not be 221 easily accommodated leading to destabilization. To study this scenario, recombinant WT and 222 I603M C4 domains were produced (Figure 2, C) and analysed by Circular Dichroism (CD) in 223 the far-UV (200-250 nm, informative about secondary structure) and near-UV (250-350 nm, 224 resulting from tertiary structure) at 25°C (Figure 3 A, B) . In agreement with the homology 225 modelling prediction, the far-UV spectrum of C4 WT showed a minimum of ellipticity at 215 226 nm, characteristic of β-sheet structure 50,51 . C4 WT and I603M spectra showed similar CD 227 spectra, suggesting that the mutation did not have major impact in the fold of the protein at 228 25ºC (Figure 3, A, B) . 229 230
The mutation p.I603M destabilizes the C4 domain 231
Thermodynamic protein stability was investigated by monitoring the CD signal at 230nm while 232 increasing temperature from 25°C to 85°C. The unfolding profiles showed a Tm of 58°C for C4 233
WT and 45°C for the I603M mutant (Figure 3, C; Supplementary Figure 1 ; For further thermodynamic characterization, we undertook refolding CD experiments by 238 ramping the temperature down after the initial heating ramp. The refolding ability of the 239 domains was determined by collecting a final far-UV CD spectrum at 25°C. Most protein 240 refolded into original secondary structure for both WT and I603M ( Supplementary Figure 2) , 241
suggesting that thermal denaturation of both proteins is a reversible process. We used the 242
Gibbs-Helmholtz equation to fit the change of ellipticity at 230 nm as a function of temperature, 243
which enabled estimation of the van't Hoff enthalpies (∆Hv). We obtained that ∆Hv of C4 WT 244 is 220 kJ/mol, whereas the value for I603M is 130 kJ/mol for C4 I603M (Table 5 ). Such 245 difference in enthalpies shows considerable thermodynamic destabilization induced by the 246 I603M mutation. 247
When the unfolding of a protein is reversible and two-state, the thermodynamic parameters 248 evaluated by CD are almost identical to the ones estimated by calorimetric methods 37 . 249
However, to confirm thermodynamic destabilization, differential scanning calorimetry (DSC) 250 experiments were carried out in the same conditions as CD experiments 39 . The thermal peaks 251 of both proteins indicate an exothermic transition with heat release, typical of protein unfolding 252 transitions (Figure 3, D) . The Tm values calculated in DSC are 58°C and 45°C for WT and 253 I603M respectively, matching the values obtained in CD. The calorimetric enthalpy (∆Hcal) 254
was calculated by integration of the area under the thermogram peak and resulted in 364 kJ/mol 255 for C4 WT and 196 kJ/mol for C4 I603M. ∆Hv was determined by a fit of the thermogram to a 256 two-state model of unfolding. Again, the ∆Hv (WT) is higher than ∆Hv (I603M), 330 kJ/mol 257 and 222 kJ/mol, respectively ( Table 5 ). The ∆Hcal/∆Hv ratio is 1.1 for WT and 0.89 for mutant, 258
suggesting that the two-state model of unfolding is a reasonable approximation to the unfolding 259 process of both proteins. The Gibbs free energy change (ΔG) of unfolding was calculated at 260 25°C considering ΔCp=0. The ΔΔG associated with the I603M mutation is 4.5 kcal/mol, 261 confirming its highly destabilizing properties. 262 263
DISCUSSION 264
In the era of Next Generation Sequencing, an ever-increasing number of variants whose 265 pathogenicity remains unclear is detected during genetic testing. In particular, many VUS that 266 have no clinical value are identified 16, 18 is a functional study to estimate the impact of mutations on a gene or protein function. 280 281
The c.1809T>G-p.I603M variant identified during genetic testing of an HCM patient was 282 classified as VUS following ACMG criteria. Hence, the variant was selected for functional 283 study to determine pathogenicity. We firstly evaluated if the c.1809T>G (p.I603M) variant 284 induce alterations in RNA splicing. During splicing, introns are removed from primary 285 transcripts, in a process that links together the flanking exons to generate mRNA 47 . During the 286 editing of pre-mRNA transcripts, the splicing machinery recognizes consensus sequences that 287 also include the exons, particularly in the regions close to the intron-exon boundaries 53 . Results 288
show that c.1809T>G-p.I603M does not induce alterations in RNA splicing (Figure 1 B, C) . 289
Regarding protein stability, the variant does not perturb much the structure of the domain at 290
25ºC, according to the far-UV and near-UV CD spectra (Figure 3 A,B) . However, the 291 thermodynamic stability of the C4 I603M mutant is severely compromised, as shown by lower 292
Tm in thermal denaturation experiments by CD and DSC (Figure 3 C,D) . Therefore, the 293 p.I603M variant alters the stability of the central C4 domain of MYBPC3, leading to more 294 frequent protein unfolding that can result in degradation of cMyBPC containing the mutation 295 I603M 54 . This scenario may lead to cMyBPC haploinsufficiency, which is believed to be a 296 major pathogenic mechanism in truncating variants 55 . Adding the functional analysis 297
supportive of a damaging effect on protein to the ACMG criteria considered for this mutation, 298
the pathogenicity assessment changes to likely pathogenic. 299 300
Remarkably, the variant p.I603M was identified in clinically affected subjects in combination 301 with the p.T33RfsX15 truncating variant of cMyBPC (Figure 1, A) . The two young subjects 302 that have only the p.I603M do not show the phenotype although, according to our results, we 303 do not exclude that they can develop the disease in the future. There is only one subject of the 304 family that has cardiac hypertrophy in the absence of the mutation p.I603M, although the 305 clinical manifestations probably are secondary to the coarctation of the aorta caused by an 306
accident. In addition, there is one patient that carries only the truncated mutation and does not 307
show HCM phenotype. This family reflects the difficulties associated with genetic testing in a 308 clinical setting. In principle, frameshift mutations in MYBPC3 are thought to be causative of 309 HCM 27 . Hence, if p.I603M is also pathogenic, two of the members of the family would be 310 compound heterozygotes for pathogenic mutations. This situation usually results in pediatric-311 onset HCM, which we did not observe in our case. This observation suggests that at least one 312 of the variants is not highly damaging. Regarding p.T33RfsX15, there has been no study on 313 whether N-terminal truncations in cMyBPC are as pathogenic as more central ones. The 314
existence of re-start of translation downstream to the mutation-driven stop codon has been 315 observed 56, 57 , which may lead to less damaging molecular phenotypes in these N-terminal 316 truncations. Regarding p.I603M, it remains to be determined how the clinical severity of a 317 mutation scales with the degree of destabilization, for which many pathogenic mutations need 318 to be analyzed. 319 320
In summary, our study shows the advantages offered by functional assessment of mutations in 321 the assignment of pathogenicity in the context of HCM. To fulfil its potential, we identify the 322 need of extensive profiling of pathogenic mutations to find molecular phenotypes, such as 323 protein destabilization 46 
